The Influence of Resveratrol on the Synovial Expression of Matrix Metalloproteinases and Receptor Activator of NF-KB Ligand in Rheumatoid Arthritis Fibroblast-Like Synoviocytes

Zeitschrift fur Naturforschung - Section C Journal of Biosciences

Volumn 68, Issue 7-8, 2013, Pages 336-342

  Glehr, Mathias ^a   Breisach, Margherita ^a   Lohberger, Birgit ^a   Friesenbichler, Joerg ^a   Leithner, Andreas ^a   Walzer, Sonja ^b   Windhager, Reinhard ^b   Fμrst, Florentine ^a   Rinner, Beate ^a   Avian, Alexander ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Matrix Metalloproteinases; Resveratrol; Rheumatoid Arthritis

Indexed keywords

MATRIX METALLOPROTEINASE; OSTEOCLAST DIFFERENTIATION FACTOR; RESVERATROL; STILBENE DERIVATIVE; TNFSF11 PROTEIN, HUMAN;

AGED; ARTICLE; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RHEUMATOID ARTHRITIS; SYNOVIUM;

AGED; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; RANK LIGAND; STILBENES; SYNOVIAL MEMBRANE;

EID: 84884231965     PISSN: 09395075     EISSN: None     Source Type: Journal    
DOI: 10.1515/znc-2013-7-812     Document Type: Article

References (39)

1. Baur J. A. and Sinclair D. A. (2006), Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discovery 5, 493-506.
2. Bereswill S., Munoz M., Fischer A., Plickert R., Haag L. M., Otto B., Kühl A. A., Loddenkemper C., Göbel U. B., and Heimesaat M. M. (2010), Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS ONE 5, 15099.
3. Bhat K. P. L., Kosmeder J. W. 2nd, and Pezzuto J. M. (2001), Biological effects of resveratrol. Antioxid. Redox Signaling 3, 1041-1064.
4. Boissy P., Andersen T. L., Abdallah B. M., Kassem M., Plesner T., and Delaisse J. M. (2005), Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res. 65, 9943-9952.
5. Bucay N., Sarosi I., Dunstan C. R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H. L., Xu W., Lacey D. L., Boyle W. J., and Simonet W. S. (1998), Oste-oprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260-1268.
6. Burger D., Dayer J. M., Palmer G., and Gabay C. (2006), Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract. Res. Clin. Rheumatol. 20, 879-896.
7. Burrage P. S., Mix K. S., and Brinckerhoff C. E. (2006), Matrix metalloproteinases: role in arthritis. Front. Biosci. 11, 529-543.
8. Byun H. S., Song J. K., Kim Y. R., Piao L., Won M., Park K. A., Choi B. L., Lee H., Hong J. H., Park J., Seok J. H., Lee Y. J., Kang S. W., and Hur G. M. (2008), Cas-pase-8 has an essential role in resveratrol-induced apoptosis of rheumatoid fibroblast-like synoviocytes. Rheumatology 47, 301-308.
9. Cardile V., Chillemib R., Lombardoa L., Sciutob S., Spataforab C., and Tringalib C. (2007), Antiproliferative activity of methylated analogues of E-and Z-resveratrol. Z. Naturforsch. 62c, 189-195.
10. Csaki C., Keshishzadeh N., Fischer K., and Shakibaei M. (2008), Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem. Pharmacol. 75, 677-687.
11. Curran S. and Murray G. I. (1999), Matrix metalloproteinases in tumour invasion and metastasis. J. Pathol. 189, 300-308.
12. Dai Z., Li Y., Quarles L. D., Song T., Pan W., Zhou H., and Xiao Z. (2007), Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine 14, 806-814.
13. Edwards J. C. (2000), Fibroblast biology. Development and differentiation of synovial fibroblasts in arthritis. Arthritis Res. 2, 344-347.
14. Elmali N., Esenkaya I., Harma A., Ertem K., Turkoz Y., and Mizrak B. (2005), Effect of resveratrol in experimental osteoarthritis in rabbits. Inflamm. Res. 54, 158-162.
15. Fiedorczyk M., Klimiuk P. A., Sierakowski S., Gindzienska-Sieskiewicz E., and Chwiecko J. (2006), Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. J. Rheumatol. 33, 1523-1529.
16. Gao X., Xu Y. X., Janakiraman N., Chapman R. A., and Gautam S. C. (2001), Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem. Pharmacol. 62, 1299-1308.
17. Glehr M., Fritsch-Breisach M., Lohberger B., Walzer S. M., Moazedi-Fuerst F., Rinner B., Gruber G., Graninger W., Leithner A., and Windhager R. (2013), Influence of resveratrol on rheumatoid fibroblastlike synoviocytes analysed with gene chip transcription. Phytomedicine, 20, 310-308.
18. Gravallese E. M., Manning C., Tsay A., Naito A., Pan C., Amento E., and Goldring S. R. (2000), Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 43, 250-258.
19. Gruber B. L., Sorbi D., French D. L., Marchese M. J., Nuovo G. J., Kew R. R., and Arbeit L. A. (1996), Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin. Immunol. Immunopathol. 78, 161-171.
20. Jang M., Cai L., Udeani G. O., Slowing K. V., Thomas C. F., Beecher C. W., Fong H. H., Farnsworth N. R., Kinghorn A. D., Mehta R. G., Moon R. C., and Pezzuto J. M. (1997), Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218-220.
21. Johnson B. A., Haines G. K., Harlow L. A., and Koch A. E. (1993), Adhesion molecule expression in human synovial tissue. Arthritis Rheum. 36, 137-146.
22. Johnson D. R., Stebulis J. A., Rossetti R. G., Burstein S. H., and Zurier R. B. (2007), Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. J. Cell. Biochem. 100, 184-190.
23. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Ka-slaris E., Kioussis D., and Kollias G. (1991), Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025-4031.
24. Kupisiewicz K., Boissy P., Abdallah B. M., Hansen F. D., Erben R. G., Savouret J. F., S0e K., Andersen T. L., Plesner T., and Delaisse J. M. (2010), Potential of resveratrol analogues as antagonists of osteoclasts and promoters of osteoblasts. Calcif. Tissue Int. 87, 437-449.
25. Lakota K., Mrak-Poljsak K., Rozman B., and Sodin-Semrl S. (2009), Increased responsiveness of human coronary artery endothelial cells in inflammation and coagulation. Mediators Inflamm. 10, 146872.
26. Lee H. Y., Jeon H. S., Song E. K., Han M. K., Park S. I., Lee S. I., Yun H. J., Kim J. R., Kim J. S., Lee Y. C., Kim S. I., Kim H. R., Choi J. Y., Kang I., Kim H. Y., and Yoo W. H. (2006), CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated os-teoclastogenesis: evidence of NF-kappaB-dependent, CD40-mediated bone destruction in rheumatoid arthritis. Arthritis Rheum. 54, 1747-1756.
27. Lin N., Sato T., Takayama Y., Mimaki Y., Sashida Y., Yano M., and Ito A. (2003), Novel anti-inflammatory actions of nobiletin, a citrus polymethoxy flavonoid, on human synovial fibroblasts and mouse macrophages. Biochem. Pharmacol. 65, 2065-2071.
28. Mizutani K., Ikeda K., Kawai Y., and Yamori Y. (1998), Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochem. Biophys. Res. Commun. 253, 859-863.
29. Murphy G., Knäuper V., Atkinson S., Butler G., English W., Hutton M., Stracke J., and Clark I. (2002), Matrix metalloproteinases in arthritic disease. Arthritis Res. 4, 39-49.
30. Palmer D. G., Selvendran Y., Allen C., Revell P. A., and Hogg N. (1985), Features of synovial membrane identified with monoclonal antibodies. Clin. Exp. Immunol. 59, 529-538.
31. Ram M., Sherer Y., and Shoenfeld Y. (2006), Matrix metalloproteinase-9 and autoimmune diseases. J. Clin. Immunol. 26, 299-307.
32. Rosengren S., Boyle D. L., and Firestein G. S. (2007), Acquisition, culture, and phenotyping of synovial fibroblasts. Methods Mol. Med. 135, 365-375.
33. Sipe J. D., Martel-Pelletier J., Otterness I. G., and Pelletier J. P. (1994), Cytokine reduction in the treatment of joint conditions. Mediators Inflamm. 3, 243-256.
34. Susa M., Luong-Nguyen N. H., Cappellen D., Zamurovic N., and Gamse R. (2004), Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J. Transl. Med. 2, 6.
35. Teitelbaum S. L. (2000), Bone resorption by osteoclasts. Science 289, 1504-1508.
36. Wang J., Gao J. S., Chen J. W., Li F., and Tian J. (2012), Effect of resveratrol on cartilage protection and apoptosis inhibition in experimental osteoarthritis of rabbit. Rheumatol. Int. 32, 1541-1548.
37. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., and Mochizuki S. (1998), Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA. 95, 3597-3602.
38. Yoshihara Y., Nakamura H., Obata K., Yamada H., Hayakawa T., Fujikawa K., and Okada Y. (2000), Matrix metalloproteinases and tissue inhibitors of met-alloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann. Rheum. Dis. 59, 455-461.
39. Zimmermann T., Kunisch E., Pfeiffer R., Hirth A., Stahl H. D., Sack U., Laube A., Liesaus E., Roth A., Palombo-Kinne E., Emmrich F., and Kinne R. W. (2001), Isolation and characterization of rheumatoid arthritis synovial fibroblasts from primary culture-primary culture cells markedly differ from fourth-passage cells. Arthritis Res. 3, 72-76.